Vaccination and rheumatic diseases: Is there still a dilemma?

Current Rheumatology Reviews

Volumn 3, Issue 1, 2007, Pages 79-91

  Conti, Fabrizio ^a   Rezai, Soheila ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Immunization; Rheumatic diseases; Rheumatoid arthritis; Systemic lupus erythematosus; Vaccination; Vaccine

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DRUG PRESERVATIVE; ETANERCEPT; GLUCOCORTICOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LA ANTIBODY; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RECOMBINANT HEPATITIS B VACCINE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SODIUM CHLORIDE; STREPTOCOCCUS VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; THIOMERSAL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPHOID PARATYPHOID VACCINE; UNINDEXED DRUG; VACCINE;

ANTIBODY PRODUCTION; ARTHRITIS; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFLICT; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; FOCAL GLOMERULONEPHRITIS; GLOMERULONEPHRITIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; MYOCARDITIS; NEPHRITIS; PAIN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK BENEFIT ANALYSIS; SIDE EFFECT; SJOEGREN SYNDROME; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 34247155191     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707779815821     Document Type: Review

References (98)

1. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1996; 24: 423-456.
2. Mounzer KC, Dinubile M. Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Rheum Dis Clin North Am 1997; 23: 259-275.
3. Bouza E, Moya JG, Muñoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15: 335-361.
4. Kong I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15: 528-534.
5. CDC. Recommended adult immunization schedule -United States, October 2005-September 2006. MMWR Morb Mortal Wkly Rep 2005; 54: Q1-Q4.
6. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. JAMA 1979; 242: 53-56.
7. Klippel JH, Karsh J, Stahl. N, Decker JL, Steinberg AD, Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in Systemic Lupus Erythematosus. Arthritis Rheum 1979; 22: 1321-1325.
8. Turner-Stokes L, Isenberg DA. Leading article: immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1988; 47: 529-531.
9. Chen RT, Pless R, DeStafano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001; 16: 309-318.
10. CDC. Prevention and control of influenza. MMWR Morb Mortal Wkly Rep 2004; 53(RR06): 1-40.
11. Older A, Battafarano DF, Enzenauer RJ, Krieg A. Can immunization precipitate connective tissue disease? Report of five cases of Systemic Lupus Erythematosus and review of the literature. Semin Arthritis Rheum 1999; 29: 131-139.
12. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996;9:699-703.
13. Shoenfeld Y, Aron-Maor A. Vaccination as an additional player in the mosaic autoimmunity. J Autoimmun 2000; 14: 1-10.
14. Altman DG. Systematic reviews of evaluations of prognostic variables. In: Egger M, Smith GD, Altman DG, Eds. Systematic reviews in health care. London. BMJ Publishing Group 200; 228-247.
15. Urowitz MB, Gladman DD, Abu-Shakra M, et al. Mortality studies in Systemic Lupus Erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997; 24: 1061-1065.
16. Ward MM, Pyun E, Studenski S. Causes of death in Systemic Lupus Erythematosus. Long-term follow up of an inception cohort. Arthritis Rheum 1995; 38: 1492-1499.
17. Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sanchez L, Jimenez-Balderas FJ, Fraga A. Infections in outpatients with Systemic Lupus Erythematosus: a prospective study. Lupus 2001; 10: 505-510.
18. Staples PJ, Gerding DN, Decker JL, Gordon RS. Incidence of infection in Systemic Lupus Erythematosus. Arthritis Rheum 1974; 17: 1-10.
19. Nived O, Sturfelt G, Wollheim F. Systemic Lupus Erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med New Series 1985; 55: 271-287.
20. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of Pneumococcal Disease. MMWR Morb Mortal Wkly Rep 1997; 46(RR08): 1-24.
21. Dillon AM, Stein HB, English RA. Splenic atrophy in Systemic Lupus Erythematosus. Ann Intern Med 1982; 96: 40-43.
22. Wachtel TJ, Fredericks R. Prediction of ventricular function from plain chest roentgenogram. R I Med J 1986; 69: 589-591.
23. Malleson P, Petty RE, Nadel H, Dimmick JE. Functional asplenia in childhood onset Systemic Lupus Erythematosus. J Rheumatol 1988; 15: 1648-1652.
24. Kamdar N, Zanzi I, Kroop S, Furie R, Margouleff D. Reversible functional asplenia in Systemic Lupus Erythematosus. Clin Nucl Med 1991; 16: 760-762.
25. Senècal JL, Chartier S, Rothfield N. Hypergammaglobulinemic purpura in systemic autoimmune diseases: predictive value of anti-Ro (SS-A) and anti-La (SS-B) antibodies and treatment with indometacin and hydroxicloroquine. J Rheumatol 1995; 22: 868-875.
26. Neilan BA, Berney SN. Hyposplenism in Systemic Lupus Erythematosus. J Rheumatol 1983; 10: 332-334.
27. Fox RA. Disseminated Lupus Erythematosus-an allergic disease? Arch Pathol 1943; 36: 311-315.
28. Ayvazian LF, Badger TL. Disseminated Lupus Erythematosus occurring among student nurses. N Engl J Med 1948; 239: 565-570.
29. Tudela P, Marti S, Bonal J. Systemic Lupus Erythematosus and vaccination against hepatitis B. Nephron 1992; 62: 236.
30. Mamoux V, Dumont C. Lupus erythémateux disséminé et vaccination contre l'hépatite B. Arch Pédiatr 1994; 1: 307-308.
31. Guiserix J. Systemic lupus erythematosus following hepatitis B vaccination. Nephron 1996; 74: 441.
32. Finielz P, Lam-Kam-Sang LF, Guiserix J. Systemic Lupus Erythematosus and thrombocitopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant 1998; 13: 2420-2421.
33. Shapiro E, Kopicky J. Comment on the article "Can immunization precipitate connective tissue disease? Report of 5 cases of Systemic Lupus Erythematosus and review of the literature". Semin Arthritis Rheum 2000; 30: 215-216.
34. Fineschi S. Can recombinant anti-HBV vaccine be a cause of Systemic Lupus Erythematosus? Lupus 2001; 10: 830.
35. Williams GW, Steinberg AD, Reinertsen JR, Klassen LW, Decker JL, Dolin R. Influenza immunization Systemic Lupus Erythematosus. Ann Intern Med 1978; 88: 729-735.
36. Brodman R, Gilfillan R, Glass D, Schur PH. Influenza vaccine response in SLE. Ann Intern Med 1978; 88: 735-741.
37. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in Systemic Lupus Erythematosus. Ann Intern Med 1978; 88: 790-792.
38. Ristow SC, Douglas RG, Candemi JJ. Influenza vaccination of patients with Systemic Lupus Erythematosus. Ann Intern Med 1978; 88: 786-789.
39. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on the disease activity. J Rheumatol 2000; 27: 1681-1685.
40. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-2557.
41. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patient with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002; 21: 369-372.
42. Mercado U, Acosta H, Avendano L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004; 56(1): 16-20.
43. Holvast B, Huckriede AL, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic hipus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-918
44. Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis Safety and immunogenicity. Vaccine 2006; 24 (16): 3217-3223.
45. Jarrett MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneumococcal vaccine in SLE. Arthritis Rheum 1980; 23: 1287-1293.
46. McDonald E, Jarrett M, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunonization in patients with Systemic Lupus Erythematosus. J Rheumatol 1984; 11: 306-308.
47. Croft SM, Schiffman G, Snyder E, Herrmann K, James K, Jarrett MP. Specific antibody response after in vivo antigenic stimulation in Systemic Lupus Erythematosus. J Rheumatol 1984; 11: 141-146.
48. Fauci AS. Immunoregulation in autoimmunity. J Allergy Clin Immunol. 1980; 66: 5-17.
49. Volkman DJ, Lane HC, Fauci AS. Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation. Proc Natl Acad Sci USA 1981; 78: 2528-2531.
50. Lane HC, Volkman DJ, Whalen G, Fauci AS. In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements. J Exp Med 1981; 154: 1043-1057.
51. Lipnick RN, Karsb J, Stahl NI, Blackwelder WC, Schiffman G, Klippel JH. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985; 12: 1118-21.
52. Battafarano DF, Battafarano NJ, Larsen L. et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-1834.
53. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis and Systemic Lupus Erythematosus. Clin Infect Dis 2002; 34: 147-153.
54. Elkayam O, Paran D, Burke M, et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005; 38(7): 493-6.
55. Teriján P, Sipka S, Maródi L, et al. No short-term immunological effects of Pneumococcus vaccination in patients with Systemic Lupus Erythematosus. Scand J Rheumatol 2002; 31: 211-215.
56. Davey ME, Bleasdale Y., Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Clin Exp Immunol 1987; 28: 562-569.
57. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982; 31(24): 317-322.
58. CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Morb Mortal Wy Rep 1991; 40(RR13): 1-19.
59. CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP). Update on hepatitis B prevention. MMWR Morb Mortal Wkly Rep 1987; 36(23): 353-366.
60. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control 1989; 17: 172-180.
61. Dentico P, Buongiorno R, Volpe A, Zavoianni A, Pastore G, Schiraldi O. Zavoianni A. Pastore G, Schiraldi O. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. Eur J Epidemiol 1992; 8: 650-655.
62. Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995; 274: 1209-1213.
63. Gartner S, Emlen W. Hepatitis B vaccination of SLE patients [abstract]. Arthritis Rheum 1996; 39(Suppl 9): S291.
64. Senécal J-L, Bertrand C, Coutlée F. Severe exacerbatíon of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al. Arthritis Rheum 1999; 42: 1307-1308.
65. Maillefert JF, Sibilia J, Toussirot E, Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al. and the letter by Senécal et al. Arthritis Rheum 2000; 43: 468-469.
66. Kelsey JL, Hochberg MC. Epidemiology of chronic musculoskeletal disorders. Annu Rev Public Health 1988; 9: 379-401.
67. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-945.
68. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293.
69. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Nad Acad Sci USA 1998; 95: 14447-14452.
70. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-2300.
71. Van Albada-Kuipers GA, Linthorst J, Peeters EA, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism Arthritis Rheum 1988; 31: 667-671.
72. Kroesen S, Widmerl AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology 2003; 42: 617-621.
73. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653-6.
74. Gross K, Combe C, Krüger K, Shattenkirchner M. Scand J Rheumatol 1995; 24: 50-52.
75. Vautier G, Carty JE. Acute sero-positive rheumatoid arthritis occurring after hepatitis B vaccination. Br J Rheumatol 1994; 33: 991-998.
76. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998; 25: 1687-1693.
77. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 1988; 31: 315-324.
78. Maillefert JF, Sibilia J, Toussirot E, et al. Rheumathic disorders developed after hepatitis B vaccination. Rheumatology 1999; 38: 978-983.
79. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 31: 1203-1206.
80. Cimmino MA, Seriolo B, Accardo S. Influenza vaccination in rheumatoid arthritis. J Rheumatol 1995; 22: 1802-1803.
81. Van der Biji AE, Gelinck LB, Breedveld FC, et al. Anti-TNF-alpha inhibits the antibody response to Influenza vaccination [abstract]. Ann Rheum Dis 2005; 64 (suppl III): 188.
82. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in Rheumatoid Arthritis: the effect of disease modifying drugs, including TNF α blockers. Ann Rheum Dis 2006; 65(2): 191-4.
83. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33: 283-288.
84. Visvanathan S, Weiss R, Keenan G, Baker D, Wagner D. Response to the pneumococcal vaccine in patients with Early Rheumatoid Arthritis [abstract]. Ann Rheum Dis 2005; 64 (suppl III): 422.
85. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-3443.
86. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jösson G, Geborek P. Influenza of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysacchride vaccine in patients with reumatoid arthritis. Rhematology 2006; 45: 106-111.
87. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 623-625.
88. Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM. Immunization of patients with Sjogren's syndrome with pneumococcal polysaccharide vaccine. Arthritis Rheum 1980; 23: 1294-1298.
89. Baum J, Gutowska G. Death in juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20(suppl): 253-255.
90. National Advisory Committee on Immunization. Statement on influenza vaccination for the 1991-1992 season. Can Dis Wkly Rep 1991; 17-24: 121-126.
91. Malleson PN, Tekano JL, Scheifele DW, Moutsopoulos HM. Influenza immunization in children with cronic arthritis: a prospective study. J Rheumatol 1993; 20: 1769-1773.
92. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheum 2001; 19: 589-594.
93. American Academy of Pediatrics: Influenza. Report of the Committee on Infectious Diseases. In: Elk Grove Village ed. Committee on Infectious Diseases 1997; 307-315.
94. American Academy of Pediatrics: Influenza. In 2000 Red Book: Report of the Committee on Infectious Diseases. 25th edition. Edited by Pickering LK. Elk Grove Village, IL: American Academy of Pediatrics 2000; 351-359.
95. Kasapçopur Ö, Çullu F, Kamburoǒlu-Goksel, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1128-1130.
96. BSR. National guidelines for the monitoring of second line drugs. London: British Society for Rheumatology 2000.
97. CDC. Using live, attenuated influenza vaccine for prevention and control of influenza. MMWR Morb Mortal Wkly Rep 2003; 52: (RR13).
98. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352: 2271-84.